 |
Cheng, A. et al. Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index. J. Med. Chem. Epub ahead of print May 11, 2010; DOI: 10.1021/jm100301x |
 |
Deng, X. et al. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. Bioorg. Med. Chem. Lett. 20, 4196-4200 (2010) |
 |
Dong, H. et al. Flavonoids activate pregnane X receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells. BMC Biochem. (2010), doi:10.1186/1471-2091-11-23 |
 |
Down, K. et al. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38α MAP kinase. Bioorg. Med. Chem. Lett. 20, 3936-3940 (2010) |
 |
Kwiatkowski, N. et al. Small-molecule kinase inhibitors provide insight into MPS1 cell cycle function. Nat. Chem. Biol. 6, 359-68 (2010) |
 |
Milkiewicz, K. et al. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg. Med. Chem. (2010), doi:10.1016/j.bmc.2010.04.087 |
 |
Murphy, E. et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci USA. 107, 4299-304 (2010) |
 |
Peddibhotla, S. et al. Inhibition of Protein Kinase C-Driven Nuclear Factor-ΚB Activation: Synthesis, Structure-Activity Relationship, and Pharmacological Profiling of Pathway Specific Benzimidazole Probe Molecules. Epub ahead of print May, 2010; J Med Chem.; DOI: 10.1021/jm1000248 |
 |
Zhou, W. et al. A Structure-Guided Approach to Creating Covalent FGFR Inhibitors. Chem & Bio 17, 285-295, (2010) |
 |
Daouti, S. et al. Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Res. 5, 1924-1932 (2009) |
 |
Shomin, C. et al. Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): Optimization and selectivity profiling. Bioorg. Med. Chem. 17, 6196-6202 (2009) |
 |
Olaharski, A. et al. Identification of a Kinase Profile that Predicts Chromosome Damage Induced by Small Molecule Kinase Inhibitors. PLoS Comput Biol. 5, 1-10 (2009) |
 |
Angell, R. et al. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. Bioorg. Med. Chem. Lett. 18, 4428–4432 (2008) |
 |
Bamborough, P. et al. Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery. J Med Chem. 51, 7898–7914 (2008) |
 |
Conway, J.G. et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 326, 41–50 (2008) |
 |
Feng, Y. et al. Discovery of Substituted 4-(Pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as Potent and Highly Selective Rho Kinase (ROCK-II) Inhibitors.J. Med. Chem. 51, 6642–6645 (2008) |
 |
Hill, R. J. et al. Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity.J Pharmacol Exp Ther. 327, 610–619 (2008) |
 |
Jiang, J.K., et al. Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 51, 8012–8018 (2008) |
 |
McDermott, U. et al. Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors. Cancer Res 9, (2008) |
 |
Rhodes, N. et al. Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. Cancer Res. 7, 2366-2374 (2008) |
 |
Schroder, G. et al. Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily. J. Med. Chem. 52, 1251–1254 (2008) |
 |
Angell, R. et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg. Med. Chem. Lett. 17, 1296–1301 (2007) |
 |
Christopher, J.A. et al. The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases. Bioorg Med Chem Lett. 17, 3972–3977 (2007) |
 |
Pan, Z. et al. Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase. ChemMedChem. 2, 58-61 (2007) |
 |
Goldstein, D. M. et al. Pathway to the Clinic: Inhibition of P38 MAP Kinase. A Review of Ten Chemotypes Selected for Development. Curr Top Med Chem. 5, 1017-1029 (2005) |